What is the 13F Pro Quality Score for SRZN?

13F Pro ranks Surrozen, Inc./DE (SRZN) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View SRZN's current score at https://13fpro.ai/company/SRZN (free sign-up required for the full ranking).

Where does 13F Pro source SRZN data?

All Surrozen, Inc./DE fundamentals and ownership data come directly from SEC EDGAR. Surrozen, Inc./DE files with the SEC under CIK 1824893. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is SRZN in?

Surrozen, Inc./DE (SRZN) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is SRZN research updated on 13F Pro?

SRZN's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Surrozen, Inc./DE(SRZN)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1824893 SRZN stock profile & AI dashboard →

13F Pro Quality Score

18.1/100

Rank #2,812 of 2,961 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why SRZN Scores 18/100

exact factor attribution · 2026-09-11

SRZN's composite is held back by profitability and free cash flow. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Earnings quality

+0.7 pts

57th pct

Institutional flow

-0.4 pts

42th pct

Shareholder dilution

-2.2 pts

6th pct

Earnings growth

-2.2 pts

5th pct

Revenue growth

-4.0 pts

30th pct

Capital efficiency

-4.9 pts

1th pct

Scale

-5.9 pts

11th pct

Free cash flow

-6.0 pts

10th pct

Profitability

-6.8 pts

5th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

SRZN Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Surrozen, Inc./DE (SRZN), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SRZN at 18.1/100 on a 32-signal composite quality model, placing it at rank #2,812 of 2,961 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Surrozen, Inc./DE reports quarterly revenue of $5.0M, net income of $50.2M, free cash flow of $-7.4M. Top institutional holders of SRZN by reported 13-F value include Column Group, TCG Crossover Management, Boxer Capital Management, based on the most recent SEC filings. SRZN trades on the Nasdaq exchange and files with the SEC under CIK 1824893. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SRZN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Surrozen, Inc./DE directly from SEC EDGAR. Surrozen, Inc./DE's 13F Pro composite quality score has ranged between 18 and 59 since 2026, currently 18.1 — a declining long-term trajectory across 8 quarterly and live scoring snapshots.

✦

Fun facts about Surrozen, Inc./DE

Quirks, history, and lore behind SRZN — the kind of stuff that makes a stock memorable.

1
The Basics
A clinical-stage biotech company · listed on Nasdaq · headquartered in South San Francisco, the self-proclaimed 'Birthplace of Biotechnology.'
2
The Numbers
A micro-cap with minimal revenue and a balance sheet that lives and dies by cash runway — the classic pre-commercial biotech math problem.
3
The History
Founded around 2018 and backed by early investors who believed a neglected signaling pathway in the body could be the key to healing damaged organs.
4
The Secret
Its entire platform is built around Wnt signaling — a fundamental biological pathway that controls tissue repair and regeneration, yet has been notoriously difficult to drug.
5
The Lore
The company's name is a mashup of 'surrogate' and 'Wnt' — because its drugs mimic the Wnt signal artificially, coaxing the body into repairing itself.
6
The Giveaway
Ticker SRZN, laser-focused on Wnt pathway therapeutics for conditions like liver and retinal disease — a small biotech swinging at a very big biological target.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$5.0M

Net Income

Q2 2026

$50.2M

Free Cash Flow

Q2 2026

$-7.4M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

-67.4% YoY

$3.5MFY 2025

FY22 $12.5MFY23 $0.00FY24 $10.7MFY25 $3.5M

Net Income

-280.8% YoY

$-242.0MFY 2025

FY22 $-36.0MFY23 $-43.0MFY24 $-63.6MFY25 $-242.0M

Operating Income

-64.8% YoY

$-42.1MFY 2025

FY22 $-44.3MFY23 $-45.8MFY24 $-25.5MFY25 $-42.1M

EPS (Diluted)

-49.4% YoY

$-32.37FY 2025

FY22 $-1.04FY23 $-21.33FY24 $-21.67FY25 $-32.37

Total Assets

+103.7% YoY

$98.7MFY 2025

FY22 $89.4MFY23 $46.1MFY24 $48.5MFY25 $98.7M

Op. Cash Flow

-71.6% YoY

$-30.2MFY 2025

FY22 $-44.1MFY23 $-40.4MFY24 $-17.6MFY25 $-30.2M

Free Cash Flow

-72.9% YoY

$-30.5MFY 2025

FY22 $-44.2MFY23 $-40.4MFY24 $-17.7MFY25 $-30.5M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$3.5M -67.4%	$10.7M	$0.00 -100.0%	$12.5M	$0.00	—
Net Income	$-242.0M -280.8%	$-63.6M -47.7%	$-43.0M -19.5%	$-36.0M +34.1%	$-54.6M -67.0%	$-32.7M
Operating Income	$-42.1M -64.8%	$-25.5M +44.2%	$-45.8M -3.2%	$-44.3M +18.5%	$-54.4M -65.8%	$-32.8M
EPS (Diluted)	$-32.37 -49.4%	$-21.67 -1.6%	$-21.33 -1956.3%	$-1.04 -604.2%	$-0.15	—
Total Assets	$98.7M +103.7%	$48.5M +5.2%	$46.1M -48.5%	$89.4M -34.8%	$137.2M +121.0%	$62.1M
Operating Cash Flow	$-30.2M -71.6%	$-17.6M +56.3%	$-40.4M +8.6%	$-44.1M +9.6%	$-48.8M -67.7%	$-29.1M
Free Cash Flow	$-30.5M -72.9%	$-17.7M +56.3%	$-40.4M +8.7%	$-44.2M +11.7%	$-50.1M -67.1%	$-30.0M

Get alerted when SRZN's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Surrozen, Inc./DE including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of SRZN

Column Group LLC
$49.7M1,916,950 sh
TCG Crossover Management, LLC
$38.2M1,473,101 sh
Boxer Capital Management, LLC
$27.0M1,105,683 sh
MILLENNIUM MANAGEMENT LLC
$17.7M683,079 sh
Point72 Asset Management, L.P.
$17.2M664,272 sh
VR Adviser, LLC
$16.4M632,931 sh
StemPoint Capital LP
$13.8M602,798 sh
PERCEPTIVE ADVISORS LLC
$13.1M503,985 sh
Spruce Street Capital LP
$11.2M432,040 sh
BlackRock, Inc.
$10.2M394,864 sh

Fund	Value	Shares
Column Group LLC	$49.7M	1,916,950
TCG Crossover Management, LLC	$38.2M	1,473,101
Boxer Capital Management, LLC	$27.0M	1,105,683
MILLENNIUM MANAGEMENT LLC	$17.7M	683,079
Point72 Asset Management, L.P.	$17.2M	664,272
VR Adviser, LLC	$16.4M	632,931
StemPoint Capital LP	$13.8M	602,798
PERCEPTIVE ADVISORS LLC	$13.1M	503,985
Spruce Street Capital LP	$11.2M	432,040
BlackRock, Inc.	$10.2M	394,864

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put SRZN on your watchlist

Track score changes the day Surrozen, Inc./DE files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is SRZN a good stock to buy?

13F Pro's AI-powered analysis of Surrozen, Inc./DE (SRZN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SRZN are available on the SRZN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. SRZN is classified as a small company.

Which hedge funds own SRZN?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SRZN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Surrozen, Inc./DE's investment landscape.